HOTH - Hoth Therapeutics shares rise on BioLexa atopic dermatitis data

Hoth Therapeutics (HOTH) announces safety results in cohort 1 of its first in human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also known as eczema.Shares up more than 8% premarket.The interim safety review indicates that BioLexa was well tolerated with no serious adverse events and no drug-related treatment-emergent adverse events observed.BioLexa has been administered twice per day for 14 days to the first ten subjects within the cohort."We are very pleased by the cohort 1 results and are proceeding as planned with submission and enrollment for cohort 2 with atopic dermatitis patients later this year," CEO Robb Knie said.

For further details see:

Hoth Therapeutics shares rise on BioLexa atopic dermatitis data